Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 40

1.

Cytochrome P450 genetic polymorphisms and the response to prasugrel: relationship to pharmacokinetic, pharmacodynamic, and clinical outcomes.

Mega JL, Close SL, Wiviott SD, Shen L, Hockett RD, Brandt JT, Walker JR, Antman EM, Macias WL, Braunwald E, Sabatine MS.

Circulation. 2009 May 19;119(19):2553-60. doi: 10.1161/CIRCULATIONAHA.109.851949. Epub 2009 May 4.

2.

Effect of intrinsic and extrinsic factors on the clinical pharmacokinetics and pharmacodynamics of prasugrel.

Small DS, Farid NA, Payne CD, Konkoy CS, Jakubowski JA, Winters KJ, Salazar DE.

Clin Pharmacokinet. 2010 Dec;49(12):777-98. doi: 10.2165/11537820-000000000-00000. Review.

PMID:
21053990
3.

Pharmacokinetic basis of the antiplatelet action of prasugrel.

Schrör K, Siller-Matula JM, Huber K.

Fundam Clin Pharmacol. 2012 Feb;26(1):39-46. doi: 10.1111/j.1472-8206.2011.00986.x. Epub 2011 Sep 5. Review.

PMID:
21895761
4.

Bedside evaluation of thienopyridine antiplatelet therapy.

Price MJ.

Circulation. 2009 May 19;119(19):2625-32. doi: 10.1161/CIRCULATIONAHA.107.696732. Review. No abstract available.

5.

Impact of genetic polymorphisms and drug-drug interactions on clopidogrel and prasugrel response variability.

Ancrenaz V, Daali Y, Fontana P, Besson M, Samer C, Dayer P, Desmeules J.

Curr Drug Metab. 2010 Oct;11(8):667-77. Review.

PMID:
20942779
6.

Metabolism and disposition of the thienopyridine antiplatelet drugs ticlopidine, clopidogrel, and prasugrel in humans.

Farid NA, Kurihara A, Wrighton SA.

J Clin Pharmacol. 2010 Feb;50(2):126-42. doi: 10.1177/0091270009343005. Epub 2009 Nov 30. Review. Erratum in: J Clin Pharmacol. 2010 Apr;50(4):483.

PMID:
19948947
7.

Comparative pharmacokinetics and pharmacodynamics of platelet adenosine diphosphate receptor antagonists and their clinical implications.

Floyd CN, Passacquale G, Ferro A.

Clin Pharmacokinet. 2012 Jul 1;51(7):429-42. doi: 10.2165/11630740-000000000-00000. Review.

PMID:
22568693
8.

Review of prasugrel for the secondary prevention of atherothrombosis.

Spinler SA, Rees C.

J Manag Care Pharm. 2009 Jun;15(5):383-95. Review.

9.

Platelet inhibitors: update on clopidogrel (Plavix) and the recently approved prasugrel (Effient).

Wynn RL.

Gen Dent. 2010 Jan-Feb;58(1):7-9. Review. No abstract available.

PMID:
20129886
10.

Implementing genotype-guided antithrombotic therapy.

Seip RL, Duconge J, Ruaño G.

Future Cardiol. 2010 May;6(3):409-24. doi: 10.2217/fca.10.6. Review.

11.

Critical review of prasugrel for formulary decision makers.

Schafer JA, Kjesbo NK, Gleason PP.

J Manag Care Pharm. 2009 May;15(4):335-43. Review.

12.

Prasugrel hydrochloride for the treatment of acute coronary syndromes.

Lhermusier T, Waksman R.

Expert Opin Pharmacother. 2015 Mar;16(4):585-96. doi: 10.1517/14656566.2015.1005602. Epub 2015 Jan 29. Review.

PMID:
25633751
13.

Advances in the monitoring of anti-P2Y12 therapy.

Harrison P.

Platelets. 2012;23(7):510-25. Epub 2012 Aug 23. Review.

PMID:
22916724
14.

Recent advances in the pharmacogenetics of clopidogrel.

Cuisset T, Morange PE, Alessi MC.

Hum Genet. 2012 May;131(5):653-64. doi: 10.1007/s00439-011-1130-6. Epub 2011 Dec 30. Review.

PMID:
22207144
15.

Pharmacotherapeutic considerations for the use of prasugrel and ticagrelor to reduce stent thrombosis in patients with acute coronary syndrome.

Piccolo R, Di Gioia G, Niglio T, D'Anna C, De Rosa R, Strisciuglio T, Bevilacqua M, Piscione F, Cirillo P, Galasso G.

Angiology. 2014 Feb;65(2):130-6. doi: 10.1177/0003319712467530. Epub 2012 Dec 4. Review.

PMID:
23221279
16.

Role of phenotypic and genetic testing in managing clopidogrel therapy.

Chan NC, Eikelboom JW, Ginsberg JS, Lauw MN, Vanassche T, Weitz JI, Hirsh J.

Blood. 2014 Jul 31;124(5):689-99. doi: 10.1182/blood-2014-01-512723. Epub 2014 Jun 20. Review.

17.

Laboratory evaluation of clopidogrel responsiveness by platelet function and genetic methods.

Smock KJ, Saunders PJ, Rodgers GM, Johari V.

Am J Hematol. 2011 Dec;86(12):1032-4. doi: 10.1002/ajh.22112. Epub 2011 Aug 2. Review.

18.

Impact of clopidogrel and potent P2Y 12 -inhibitors on mortality and stroke in patients with acute coronary syndrome or undergoing percutaneous coronary intervention: a systematic review and meta-analysis.

Aradi D, Komócsi A, Vorobcsuk A, Serebruany VL.

Thromb Haemost. 2013 Jan;109(1):93-101. doi: 10.1160/TH12-06-0377. Epub 2012 Nov 29. Review.

PMID:
23197191
19.

Pharmacodynamic effect and clinical efficacy of clopidogrel and prasugrel with or without a proton-pump inhibitor: an analysis of two randomised trials.

O'Donoghue ML, Braunwald E, Antman EM, Murphy SA, Bates ER, Rozenman Y, Michelson AD, Hautvast RW, Ver Lee PN, Close SL, Shen L, Mega JL, Sabatine MS, Wiviott SD.

Lancet. 2009 Sep 19;374(9694):989-97. doi: 10.1016/S0140-6736(09)61525-7. Epub 2009 Aug 31. Review.

PMID:
19726078
20.

Thienopyridine antiplatelet agents: focus on prasugrel.

Freeman MK.

Consult Pharm. 2010 Apr;25(4):241-57. doi: 10.4140/TCP.n.2010.241. Review.

PMID:
20511177

Supplemental Content

Support Center